
Michael J Grayling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2720689/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ: British Medical Journal, 2018, 363, k1614.	2.3	235
2	Stepped wedge cluster randomized controlled trial designs: a review of reporting quality and design features. Trials, 2017, 18, 33.	1.6	51
3	A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials. Journal of the National Cancer Institute, 2019, 111, 1255-1262.	6.3	35
4	A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials. American Statistician, 2021, 75, 424-432.	1.6	25
5	Do singleâ€arm trials have a role in drug development plans incorporating randomised trials?. Pharmaceutical Statistics, 2016, 15, 143-151.	1.3	22
6	phaseR: An R Package for Phase Plane Analysis of Autonomous ODE Systems. R Journal, 2014, 6, 43.	1.8	18
7	A review of available software for adaptive clinical trial design. Clinical Trials, 2020, 17, 323-331.	1.6	14
8	A web application for the design of multi-arm clinical trials. BMC Cancer, 2020, 20, 80.	2.6	12
9	Group sequential designs for stepped-wedge cluster randomised trials. Clinical Trials, 2017, 14, 507-517.	1.6	10
10	Blinded and unblinded sample size reestimation procedures for steppedâ€wedge cluster randomized trials. Biometrical Journal, 2018, 60, 903-916.	1.0	10
11	Quality of stepped-wedge trial reporting can be reliably assessed using anÂupdated CONSORT: crowd-sourcing systematic review. Journal of Clinical Epidemiology, 2019, 107, 77-88.	5.0	9
12	Impact of the COVID-19 lockdown on hangings attended by emergency medical services. Resuscitation, 2020, 157, 89-90.	3.0	8
13	Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential. BMC Rheumatology, 2021, 5, 21.	1.6	8
14	Blinded and unblinded sample size reestimation in crossover trials balanced for period. Biometrical Journal, 2018, 60, 917-933.	1.0	7
15	An optimised multi-arm multi-stage clinical trial design for unknown variance. Contemporary Clinical Trials, 2018, 67, 116-120.	1.8	6
16	Admissible multiarm steppedâ€wedge cluster randomized trial designs. Statistics in Medicine, 2019, 38, 1103-1119.	1.6	6
17	Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials. Statistics in Medicine, 2022, , .	1.6	5
18	Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately. JCO Precision Oncology, 2021, 5, 1813-1820.	3.0	5

MICHAEL J GRAYLING

#	Article	IF	CITATIONS
19	Adaptive Designs: Benefits and Cautions for Neurosurgery Trials. World Neurosurgery, 2022, 161, 316-322.	1.3	4
20	Characterising the allergic profile of children with cystic fibrosis. Immunity, Inflammation and Disease, 2021, , .	2.7	3
21	Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials. BMC Cancer, 2022, 22, 111.	2.6	3
22	Group sequential crossover trial designs with strong control of the familywise error rate. Sequential Analysis, 2018, 37, 174-203.	0.5	2
23	Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies. Statistics in Biopharmaceutical Research, 2019, 11, 360-374.	0.8	2
24	A stochastically curtailed twoâ€∎rm randomised phase II trial design for binary outcomes. Pharmaceutical Statistics, 2021, 20, 212-228.	1.3	2
25	Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. Pharmaceutical Statistics, 2021, 20, 990-1001.	1.3	2
26	Accounting for variation in the required sample size in the design of group-sequential trials. Contemporary Clinical Trials, 2021, 107, 106459.	1.8	2
27	Ambulance documentation of stroke symptoms during the UK COVID-19 â€~Stay at Home' message. Emergency Medicine Journal, 2021, 38, 83-84.	1.0	2
28	Response adaptive intervention allocation in steppedâ€wedge cluster randomized trials. Statistics in Medicine, 2022, 41, 1081-1099.	1.6	2
29	A stochastically curtailed singleâ€arm phase II trial design for binary outcomes. Journal of Biopharmaceutical Statistics, 2022, 32, 671-691.	0.8	2
30	Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study. Trials, 2019, 20, 665.	1.6	1
31	Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables. Communications in Statistics - Theory and Methods, 2021, 50, 18-34.	1.0	1
32	Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials. British Journal of Cancer, 2022, 126, 204-210.	6.4	1
33	Optimised point estimators for multi-stage single-arm phase II oncology trials. Journal of Biopharmaceutical Statistics, 2022, 32, 817-831.	0.8	1
34	Mind the gap: covariate constrained randomisation can protect against substantial power loss in parallel cluster randomised trials. BMC Medical Research Methodology, 2022, 22, 111.	3.1	1
35	Calculations Involving the Multivariate Normal and Multivariate t Distributions with and without Truncation. The Stata Journal, 2018, 18, 826-843.	2.2	0
36	Group Sequential Clinical Trial Designs for Normally Distributed Outcome Variables. The Stata Journal, 2018, 18, 416-431.	2.2	0

#	Article	IF	CITATIONS
37	Re-formulating Gehan's design as a flexible two-stage single-arm trial. BMC Medical Research Methodology, 2019, 19, 22.	3.1	0
38	When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay. European Journal of Cancer, 2022, 166, 270-278.	2.8	0
39	Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial. BMC Rheumatology, 2021, 5, 54.	1.6	0